Panviprep

Panviprep

The PANVIPREP consortium incorporates 14 European partners with complementary expertise in virology, structural biology, medicinal chemistry, pharmacology, and machine-learning approaches. Together, they aim to contribute to antiviral pandemic preparedness by piloting and progressing antiviral drug development, in particular through

  •     developing and advancing broad(er)-spectrum antiviral compounds targeting five selected RNA virus families with high epidemic or pandemic potential;
  •     delivering novel RNA virus knowledge and tools, including molecules that block novel molecular targets in the viral replication cycle;
  •     implementing technological innovations to accelerate antiviral drug discovery and development.

 

Panviprep website
Nosevac

Nosevac

The NOSEVAC consortium, operating under the coordination of the European Vaccine Initiative (EVI), endeavours to cultivate and evaluate inventive nasal vaccine platforms as a ground-breaking approach to prevent the earliest stage of infection, thereby inhibiting upper respiratory tract colonisation, transmission, and disease. The project relies upon a distinctive consortium comprising 12 distinguished and complementary research teams hailing from the European Union (EU), UK and Switzerland.

  Funding from the EU, the UK and Swiss governments allowed the project launch which, in addition to develop new nasal vaccine candidates, will:

  •   Develop vaccine formulations for nasal delivery of RNA- and protein-based antigens
  •   Discover bacterial antigens that promote colonisation of the upper respiratory tract
  •   Identify human host immune factors for long-term protection of the upper respiratory tract
  •   Address acceptability of nasal vaccination

It is expected that NOSEVAC will establish strategic research pathways to combat respiratory pathogens, encompassing those with the potential for large outbreaks. Furthermore, the organisation will serve as a catalyst for evidence-driven decision-making for policymakers and investors.

Nosevac website
MACRAMÉ

MACRAMÉ

The MACRAMÉ Project is fully aligned with the EU ambitions to secure the safety and sustainability of new chemicals, materials, products and processes in order to strive for zero pollution and toxic-free environments, as addressed in the EU’s Chemical Strategy for Sustainability (2020), and in the European Green Deal (2019 & 2021); in doing so, the Project concentrates on methodologies that are applicable to nanomaterials, and widens them to ‘Advanced Materials’ (AdMas) ⎼ a material category that includes but surpasses that of ‘nanomaterials’ (EU, ‘Definition of a Nanomaterial’) – in commercialised products and that are aligned with the future-oriented innovation, safety and sustainability considerations of the OECD (OECD (2020)), the EU (EU (2022)), and several of its Member States (e.g. Germany (2021)).

This will be achieved through development and demonstration of novel methodologies, and by advancing their harmonisation & standardisation on three MACRAMÉ Material Families of inhalable carbon-based AdMas of various morphologies and dimensions (Tiwari et al. (2012)), beyond spherical particles: (a) graphene-related material (GRM), (b) carbon nanofibres (CNFs), e.g., carbon nanotubes (CNTs), and (c) Poly Lactic-co-Glycolic Acid (nano)particles (PLGA). The focus on carbon-based AdMas addresses unsolved detection and characterisation issues, especially in complex media. In doing so, MACRAMÉ builds on >15 years of research and innovation (R&I) and knowledge pooling in nanosafety, formed through numerous European and international collaborations. MACRAMÉ will add value to the results of collaborations, such as the Malta-Initiative, and the Graphene Flagship Validation Service and Standardisation Committee, to proactively support EU industries in becoming world-leaders in clean technologies and products and achieving the Green Deal’s ambitious timeline.

MACRAMÉ website
FAIR

FAIR

Epithelix is partner of the FAIR consortium.
FAIR is an EU Horizon 2020 project that aims at evaluating the activation of the innate immune system in the airways. FAIR aims at providing an alternative adjunct strategy to standard of care antibiotics for treating pneumonia caused by antibiotic-resistant bacteria.

FAIR website
ORGANOVIR

ORGANOVIR

Epithelix is partner of the Organovir consortium.
OrganoVIR is a Horizon 2020 Marie Sklowdowska-Curie Actions Innovative Training Network (MSCA-ITN), that trains 15 Early Stage Researchers to lead innovation in the field of organoids for virology.
Organovir's mission is to transform the virology landscape and establish human organoids as superior models for virus research.

Organovir website
ONCONANOSCREEN

ONCONANOSCREEN

Epithelix is partner of the Onconanoscreen consortium.
Onconanoscreen is an interreg project linking Swiss and French research groups.
Onconanoscreen's mission is to develop an in vitro platform to screen nanotherapies against lung cancer.

Onconanoscreen website
ONCOTHEIS

ONCOTHEIS

OncoTheis is a biotech company dedicated to developing innovative bioengineered tissues and organoids for the many challenges in cancer research. OncoTheis is producing a new generation of integrated 3D in vitro models that combine both healthy and compromised tissues in order to accurately simulate the in vivo situation.

Oncotheis website
Ligue suisse contre la vivisection

Ligue suisse contre la vivisection

The goal of "La ligue suisse contre la vivisection" is to fight, with all the possible legal means, against the practice of vivisection such as the use of animals for medical, scientific, military, industrial or commercial purposes, until the total abolition of such practices. It recognizes and financially helps the creation and development of alternative methods to animal testing.

 

LSCV website
FENRIV

FENRIV

In order to limit vivisection, Mr Egon Naef foundation helps researchers and scientists to develop alternative experimental methods to animal testing. Naef Foundation also encourages all researchers to use these alternative methods, especially the in vitro ones, within the framework of their research. Naef Foundation gives each year a prize to a scientist whose contributions were significant to the development of these alternative methods.

Fenriv website
Pro anima / Ethic Science

Pro anima / Ethic Science

Pro Anima is an apolitical and independent scientific board dedicated to develop human biomedical research by promoting alternatives to animal experimentation. Pro Anima has been active for more than 25 years using all the possible tools to raise awareness about animal testing and existing alternatives: social networks, stands, poster campaign petitions, medias, among other initiatives.

Pro Anima website
ESTIV

ESTIV

The European Society of Toxicology In Vitro is the leading organization in Europe that strengthens the scientific network of in vitro toxicologists and promotes in vitro toxicology, both scientifically and educationally in all countries of Europe.

Vitrocell Systems

Vitrocell Systems

Vitrocell systems offers customers from industry and research institutes new culture and exposure systems for in vitro studies on gases or complex mixtures. The VITROCELL modules adapted to MucilAir™ and SmallAir™ provide new possibilities for characterizing the effects of airborne substances such as gas, nanoparticles and complex mixtures.

Vitrocell website
Bill & Melinda Gates Foundation

Bill & Melinda Gates Foundation

The Bill & Melinda Gates Foundation financially supports Epithelix research efforts to fight against COVID-19.

As principal investigator, Epithelix coordinates the research efforts of several BSL-3 laboratories to screen promising antivirals against SARS-CoV-2.

BMGF website
ATRA

ATRA

ATRA is a Swiss association founded in 1978 in Lugano.

Its goal is to fight, with all the possible legal means, against the practice of vivisection such as the use of animals for medical, scientific, military, industrial or commercial purposes, until the total abolition of such practices. It recognizes and financially helps the creation and development of alternative methods to animal testing.

ATRA website
AnimalFree Research

AnimalFree Research

For more than 40 years their commitment to the welfare and dignity of experimental animals constitues the basis for all the AnimalFree Research's activities. They are seeking dialog and cooperation, respect other positions but do not compromise their principles.

AnimalFree Research website
Virnext

Virnext

VirNext is a spin-off (EZUS Lyon) of Université Claude Bernard Lyon 1 (UCBL1) created within the VirPath laboratory.

Epithelix partners with VirNext to provide in vitro testing for SARS-CoV-2 infection using BSL-3 facility.

VirNext website
BioPark

BioPark

BioPark centralizes means and skills in the domain of life sciences.

Epithelix partners with BioPark to provide cutting edge chemical analysis (MALDI MS and MS/MS) on in vitro airway models.

BioPark website